Retraction Note: A synthetic dsRNA, as a TLR3 pathwaysynergist, combined with sorafenib suppresses HCC in vitro and in vivo (BMC Cancer, (2013), 13, 1, (527), 10.1186/1471-2407-13-527);A synthetic dsRNA, as a TLR3 pathwaysynergist, combined with sorafenib suppresses HCC in vitro and in vivo

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Xu, Yu Yin ^a   Chen, Li ^a   Wang, Gui Lan ^a   Zhou, Jia Ming ^a   Zhang, Yi Xin ^a   Wei, Yin Ze ^a   Zhu, Yuan Yuan ^b   Qin, Jing ^a  

^a NANTONG UNIVERSITY   (China)

^b Biomics (Nantong) Co Ltd   (China)

Author keywords

dsRNA; HCC; NF B; sorafenib; TLR3

Indexed keywords

ANTINEOPLASTIC AGENT; BM 06; CASPASE 8; CYCLINE; DOUBLE STRANDED RNA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON; PROTEIN BCL 2; SORAFENIB; SURVIVIN; TOLL LIKE RECEPTOR 3; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL MIGRATION; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; LIVER CELL CARCINOMA; MALE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN RNA BINDING; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA SYNTHESIS;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CASPASE 8; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; GENE EXPRESSION; HUMANS; INTERFERON-GAMMA; LIVER NEOPLASMS; MALE; NF-KAPPA B; NIACINAMIDE; PHENYLUREA COMPOUNDS; RATS; RNA, DOUBLE-STRANDED; TOLL-LIKE RECEPTOR 3; TRANSCRIPTIONAL ACTIVATION; TUMOR BURDEN;

EID: 84887066948     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-023-11135-3     Document Type: Erratum

References (41)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics 2002. CA Cancer J Clin 2005, 55:74-108. 10.3322/canjclin.55.2.74, 15761078.
2. El Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999, 340:745-750. 10.1056/NEJM199903113401001, 10072408.
3. Sherman M. Hepatocellular carcinoma: epidemiology, risk factors, and screening. Semin Liver Dis 2005, 25:143-154. 10.1055/s-2005-871194, 15918143.
4. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90. 10.3322/caac.20107, 21296855.
5. Kawano Y, Sasaki A, Kai S, et al. Prognosis of patients with intrahepatic recurrence after hepatic resection for hepatocellular carcinoma: a retrospective study. Eur J Surg Oncol 2009, 35(2):174-179. 10.1016/j.ejso.2008.01.027, 18325724.
6. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007, 132(7):2557-2576. 10.1053/j.gastro.2007.04.061, 17570226.
7. Takenaka K, Kawahara N, Yamamoto K, et al. Results of 280 liver resections for hepatocellular carcinoma. Arch Surg 1996, 131(1):71-76. 10.1001/archsurg.1996.01430130073014, 8546582.
8. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatol 2005, 42:1208-1236.
9. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003, 362:1907-1917. 10.1016/S0140-6736(03)14964-1, 14667750.
10. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatol 2003, 37:429-442.
11. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008, 359:378-390. 10.1056/NEJMoa0708857, 18650514.
12. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004, 64(19):7099-7109. 10.1158/0008-5472.CAN-04-1443, 15466206.
13. Alavi A, Hood JD, Frausto R, Stupack DG, Cheresh DA. Role of Raf in vascular protection from distinct apoptotic stimuli. Science 2003, 301(5629):94-96. 10.1126/science.1082015, 12843393.
14. Betsholtz C. Insight into the physiological functions of PDGF through genetic studies in mice. Cytokine Growth Factor Rev 2004, 15(4):215-228. 10.1016/j.cytogfr.2004.03.005, 15207813.
15. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005, 353:1673-1684. 10.1056/NEJMoa052122, 16236738.
16. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350:2335-2342. 10.1056/NEJMoa032691, 15175435.
17. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005, 353:123-132. 10.1056/NEJMoa050753, 16014882.
18. Yamamoto M, Sato S, Hemmi H, et al. Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. Science 2003, 301(5633):640-643. 10.1126/science.1087262, 12855817.
19. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NFkappaB by Toll-like receptor 3. Nature 2001, 413(6857):732-738. 10.1038/35099560, 11607032.
20. Heylbroeck C, Balachandran S, Servant MJ, et al. The IRF-3 transcription factor mediates Sendai virus-induced apoptosis. J Virol 2000, 74(8):3781-3792. 10.1128/JVI.74.8.3781-3792.2000, 111887, 10729153.
21. Salaun B, Coste I, Rissoan MC, Lebecque SJ, Renno T. TLR3 can directly trigger apoptosis in human cancer cells. J Immunol 2006, 176(8):4894-4901.
22. Salaun B, Lebecque S, Matikainen S, Rimoldi D, Romero P. Toll-like receptor 3 expressed by melanoma cells as a target for therapy?. Clin Cancer Res 2007, 13(15 pt 1):4565-4574.
23. Wilhelm S, Carter C, Lynch M, Lowinger T, Dumas J, Smith RA, et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 2006, 5:835-844. 10.1038/nrd2130, 17016424.
24. Krieg AM. Toll-like receptor 9 (TLR9) synergists in the treatment of cancer. Oncogene 2008, 27(2):161-167. 10.1038/sj.onc.1210911, 18176597.
25. Kanzler H, Barrat FJ, Hessel EM, Coffman RL. Therapeutic targeting of innate immunity with Toll-like receptor synergists and antsynergists. Nat Med 2007, 13(5):552-559. 10.1038/nm1589, 17479101.
26. Killeen SD, Wang JH, Andrews EJ, Redmond HP. Exploitation of the toll-like receptor system in cancer: a doubled-edged sword?. Br J Cancer 2006, 95(3):247-252. 10.1038/sj.bjc.6603275, 2360630, 16892041.
27. Gale M, Foy EM. Evasion of intracellular host defence by hepatitis C virus. Nature 2005, 436(7053):939-945. 10.1038/nature04078, 16107833.
28. Raskopf E, Vogt A, Sauerbruch T, Schmitz V. siRNA targeting VEGF inhibits hepatocellular carcinoma growth and tumor angiogenesis in vivo. J Hepatol 2008, 49(6):977-84. 10.1016/j.jhep.2008.07.022, 18845354.
29. Sass G, Leukel P, Schmitz V, et al. Inhibition of heme oxygenase 1 expression by small interfering RNA decreases orthotopic tumor growth in livers of mice. Int J Cancer 2008, 123(6):1269-1277. 10.1002/ijc.23695, 18566988.
30. Arbuthnot P, Ely A, Weinberg MS. Hepatic delivery of RNA interference activators for therapeutic application. Curr Gene Ther 2009, 9(2):91-103. 10.2174/156652309787909517, 19355867.
31. Ferreon JC, Ferreon AC, Li K, Lemon SM. Molecular determinants of TRIF proteolysis mediated by the hepatitis C virus NS3/4A protease. J Biol Chem 2005, 280(21):20483-20492. 10.1074/jbc.M500422200, 15767257.
32. Furrie E, Macfarlane S, Thomson G, Macfarlane GT, Microbiology & Gut Biology Group Tayside tissue & tumour bank. Toll-like receptors-2, -3 and -4 expression patterns on human colon and their regulation by mucosal-associated bacteria. Immunology 2005, 115(4):565-574. 10.1111/j.1365-2567.2005.02200.x, 1782176, 16011525, Microbiology & Gut Biology Group.
33. Uno T, Hirabayashi K, Murai M, Yano J, Ozato K. The role of IFN regulatory factor-3 in the cytotoxic activity of NS-9, a polyinosinic-polycytidylic acid/cationic liposome complex, against tumor cells. Mol Cancer Ther 2005, 4(5):799-805. 10.1158/1535-7163.MCT-04-0317, 15897244.
34. Khvalevsky EZ, Abramovitch R, Barash H, et al. Toll-like receptor 3 signaling attenuates liver regeneration. Hepatology 2009, 50(1):198-206. 10.1002/hep.22973, 19441101.
35. Khvalevsky E, Rivkin L, Rachmilewitz J, Galun E, Giladi H. TLR3 signaling in a hepatoma cell line is skewed towards apoptosis. J Cell Biochem 2007, 100(5):1301-1312. 10.1002/jcb.21119, 17243100.
36. Ashkenazi A, Herbst R. To kill a tumor cell: the potential of proapoptotic receptor synergist. J Clin Invest 2008, 118:1979-1990. 10.1172/JCI34359, 2396896, 18523647.
37. Yoneda K, Sugimoto K, Shiraki K, et al. Dual topology of functional toll like receptor 3 expression in human hepatocellular carcinoma: differential signaling mechanisms of TLR3-induced NF-kappaB activation and apoptosis. Int J Oncol 2008, 33(5):929-936.
38. Vercammen E, Staal J, Beyaert R. Sensing of viral infection and activation of innate immunity by toll-like receptor 3. Clin Microbiol Rev 2008, 21(1):13-25. 10.1128/CMR.00022-07, 2223843, 18202435.
39. Bergé M, Bonnin P, Sulpice E, et al. Small interfering RNAs induce target independent inhibition of tumor growth and vasculature remodeling in a mouse model of hepatocellular carcinoma. Am J Pathol 2010, 177(6):3192-3201. 10.2353/ajpath.2010.100157, 2993283, 20971743.
40. Chin AI, Miyahira AK, Covarrubias A, et al. Toll-like receptor 3-mediated suppression of TRAMP prostate cancer shows the critical role of type I interferons in tumor immune surveillance. Cancer Res 2010, 70(7):2595-2603. 10.1158/0008-5472.CAN-09-1162, 2995454, 20233880.
41. Kleinman ME, Yamada K, Takeda A, et al. Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature 2008, 452(7187):591-597. 10.1038/nature06765, 2642938, 18368052.